News & insights
Check out our latest updates
Cambridge Cognition joins Imperial College-led NHS study bringing earlier Alzheimer’s diagnosis into primary care
Cambridge Cognition joins an Imperial College-led NHS study exploring how to bring earlier Alzheimer’s diagnosis into primary care.
Measuring speech in schizophrenia spectrum disorders
A practical guide to speech features, elicitation tasks and study design
First new CANTAB® product features developed & launched from the landmark INTUITION project
First new CANTAB® product features developed & launched from the landmark INTUITION project Cambridge Cognition (AIM: COG), the neuroscience technology company, announces two new product features for its CANTAB digital cognitive assessments derived from analysis of data from the INTUITION project. ​​​Application of Expanded Normative Dataset – Increased Sensitivity and...
C2N Diagnostics Expands Global Partnerships in United Kingdom on World Alzheimer’s Day, Joins Cambridge Cognition and The Alzheimer’s Trust to Improve Alzheimer’s Disease Diagnosis
Collaboration integrates cognitive assessment, proprietary blood test, national phlebotomy and MRI infrastructure to accelerate patient diagnosis and care pathways throughout the UK.
Integrating Blood-Based Biomarkers & Digital Cognitive Assessments to Accelerate Brain Health Research
The Convergence: Integrating Blood Biomarker Tests and Digital Cognition to Accelerate Alzheimer’s Research The paradigm for diagnosing and monitoring Alzheimer’s disease (AD) is shifting from relying on clinical symptoms to incorporating definitive biological evidence of amyloid and tau proteinopathy. As discussed in our recent joint webinar with C2N Diagnostics and...
